Beta Cell Replacement Therapies Workshop
The purpose of this workshop is to bring the academic, industry, and regulatory communities together to discuss issues relevant to the replacement of highly functional islet cell sources, other than purified human pancreatic islets manufactured from deceased donor pancreases, to treat type 1 diabetes and other insulin-deficient forms of diabetes. The workshop will highlight remaining translational gaps and ways to accelerate bringing cell-based therapies to patients.
- How do we show some human proof of concept for beta-cell replacement that does not require broad, long-term systemic immunosuppression with a renewable cell source?
- What are the gaps, and what do we need to understand? What are we learning?
- How do we move from first-generation to next-generation products? How do we accelerate translation?
Guillermo Arreaza-Rubin, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nancy Bridges, M.D., National Institute of Allergy and Infectious Diseases
Thomas Eggerman, M.D., Ph.D., NIDDK
Ron Gill, Ph.D., University of Colorado, co-chair
Elizabeth Hart, M.D., U.S. Food and Drug Administration
Albert Hwa, Ph.D., NIDDK
Esther Latres, Ph.D., JDRF
Marjana Marinac, Pharm.D., JDRF
Michael Rickels, M.D., University of Pennsylvania, co-chair
Sheryl Sato, Ph.D., NIDDK
Meeting Summary (PDF, 347 KB)
May 10, 2022
Natcher Conference Center
Bethesda, MD 20894
T: +1-(301) 402-0911
This is a hybrid workshop. Virtual participation is available. If attending via webinar, the web link needed to join will be distributed via email prior to the date of the event.
Guillermo Arreaza-Rubin, M.D.
Albert Hwa, Ph.D.
The Scientific Consulting Group, Inc.